L.A. Mckeown

Numerous opportunities exist for improving quality of care for patients and cath lab teams, says Andrew Einstein.

The data hint at sirolimus becoming a useful option or even a replacement for paclitaxel, but full 5-year follow-up is needed.

Fewer rehospitalizations and better functional and QoL outcomes point to TAVI as a good choice, but longer-term data are needed.

While men are likely to rely on the judgment of their spouse, women tend to seek out advice from others.

The data thus far suggest fewer repeat interventions with the newly FDA approved resorbable device compared with PTA.

The highly comorbid “no-option” patients have seen sustained pain reduction and avoided amputation.

The highly comorbid “no-option” patients have seen sustained pain reduction and avoided amputation.

The heat-map data can be used at local levels to educate representatives about the amputation rates in their area.

The results in patients with long, complex lesions are better than or equal to those of surgery, but without the complications.

In high- and standard-risk patients CAS and TCAR look good, but some worry about skill sets, learning curves, and territorialism.